Pacific Biosciences shows a perfect recent earnings beat streak and analyst-projected upside, but persistent cash burn below the quality floor and heavy bearish positioning in a volatile stock temper the case for near-term conviction.
Thesis pillars
- Cash Burn Quality Floor Breach→Stable
- Perfect Earnings Beat Streak→Stable
- Analyst Upside Despite Light Coverage→Stable
- +2 more pillars — see the Why tab for full reasoning
Pacific Biosciences of Californ (PACB) Stock Analysis
Inst Constrain edge
Healthcare · Medical Devices
Sell if holding. Engine safety override at $1.66: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 1.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 22%; Below-average business quality; Below long-term trend. (Note: Risk dimension 1.9/10 and A.R:R 1.8:1 are different metrics that happen to read the same number here.)
Pacific Biosciences (PacBio) is a life science technology company that designs, develops, and manufactures HiFi long-read DNA sequencing systems, including its Revio, Vega, and Sequel instruments, serving academic, government, clinical, and pharmaceutical customers researching... Read more
Sell if holding. Engine safety override at $1.66: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 1.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 22%; Below-average business quality; Below long-term trend. (Note: Risk dimension 1.9/10 and A.R:R 1.8:1 are different metrics that happen to read the same number here.) Chart setup: No clear chart pattern; technical signals are mixed. Score 4.6/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 32d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
About Pacific Biosciences of Californ
About Pacific Biosciences of Californ
Pacific Biosciences ended 2025 with a $49.2 million order backlog, of which it expects to convert approximately 80% to revenue in 2026, after completing a $50.0 million asset sale of its short-read DNA sequencing technology to Illumina Cambridge in January 2026 that narrowed the company to long-read HiFi sequencing. PacBio's Revio, Vega, and Sequel instruments, along with SMRT Cell and reagent consumables, serve academic, government, clinical, and pharmaceutical customers researching human genomics, oncology, infectious disease, and agricultural genetics.
PacBio earns revenue from instrument sales alongside recurring, high-margin SMRT Cell and reagent consumables that customers purchase per sequencing run, distributed through a global direct sales force and regional distribution partners across Australia, Asia, Europe, the Middle East, and the Americas. The company holds or exclusively licenses 450 issued U.S. patents covering its Single-Molecule Real-Time (SMRT) sequencing technology, and competes against Illumina, BGI Genomics, Thermo Fisher, Oxford Nanopore, Roche, Qiagen, Element Biosciences, Bionano Genomics, Ultima Genomics, and 10x Genomics. PacBio recorded $15.0 million of impairment charges in 2025 following $184.5 million in 2024, along with $359.3 million of accelerated amortization tied to the 2021 Omniome acquisition, reflecting a period of portfolio rationalization alongside expense-reduction plans initiated in 2024 and 2025.
Show full overview
PacBio's 10-K discloses that no single customer accounted for 10% or more of total revenue in 2025, 2024, or 2023, indicating a diversified academic, government, and commercial customer base, but the company also discloses that some components required in its instruments and consumables are currently sole-sourced or single-sourced, an exposure it manages around at its Menlo Park, California facility using domestic and international subcontract manufacturers. With over $640 million in convertible notes outstanding as of December 31, 2025 and continuing net losses, any sole-source component disruption would compound an already capital-constrained balance sheet.
See also: Healthcare · Medical Devices
From Pacific Biosciences of Californ's most recent 10-K filing, extracted July 6, 2026.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSuppliersole-sourced or single-sourced components10-K Item 1: 'Some of the components required in our products are currently either sole sourced or single sourced.'
Material Events(8-K, last 90d)
- 2026-06-04Item 5.02LOWPacBio's Board approved, and stockholders ratified at the June 3, 2026 Annual Meeting, an amendment to the 2020 Equity Incentive Plan reserving an additional 16,000,000 shares for issuance. The item covers only the compensatory plan amendment; no officer departure or appointment was involved.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
5 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Volatile — 7.5% daily ATR makes tight stops impractical. Position-size conservatively.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Unprofitable operations — net margin -80.3%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $1.66: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 1.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 22%; Below-average business quality; Below long-term trend. (Note: Risk dimension 1.9/10 and A.R:R 1.8:1 are different metrics that happen to read the same number here.) Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $1.56. Score 4.6/10, moderate confidence.
Take-profit target: $2.14 (+27.4% upside). Prior stop was $1.56. Stop-loss: $1.56.
Concentration risk — Supplier: sole-sourced or single-sourced components; Quality below floor (2.8 < 4.0); Value-trap signals (2/5): High leverage (D/E 3.4), Material insider selling (10 sells, 0.20% of cap).
Pacific Biosciences of Californ trades at a P/E of N/A (forward -4.2). TrendMatrix value score: 8.6/10. Verdict: Sell.
15 analysts cover PACB with a consensus score of 3.8/5. Average price target: $2.
What does Pacific Biosciences of Californ do?Pacific Biosciences (PacBio) is a life science technology company that designs, develops, and manufactures HiFi...
Pacific Biosciences (PacBio) is a life science technology company that designs, develops, and manufactures HiFi long-read DNA sequencing systems, including its Revio, Vega, and Sequel instruments, serving academic, government, clinical, and pharmaceutical customers researching human genomics, oncology, infectious disease, and agricultural genetics. In January 2026, PacBio completed the $50 million sale of its short-read sequencing technology assets to Illumina Cambridge, narrowing its focus to long-read HiFi sequencing. The company recorded a $15.0 million impairment charge in 2025 and continu